Paolo Zola, MD, Università degli Studi di Torino, Turin, Italy, discusses potential future directions of his randomized control trial (RCT) comparing minimalist versus intensive follow-up management of patients treated for gynecological cancer. An increasing awareness of tumor biology that has the potential to impact treatment options may need to be considered in the future; the diagnostic/screening methods used could be reassessed to account for molecular and genetic tumor information,which may impact the significance of results. In the near future, subgroup analysis of this very large RCT could also be considered to assess whether factors such as race influence results. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
